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Abstract LIM-kinase 1 (LIMK1) is a serine/threonine kinase 
containing two LIM motifs at the N-terminus. The functional 
role of LIMK1 has remained unknown. In this study, we 
examined the role of LIMK1 in cell growth of fibroblasts. 
Induced expression of LIMK1 in NIH3T3 cells led to growth 
retardation• Transfection of LIMK1 sense cDNA into NIH3T3 
and H-ras-transformed FYJ10 fibroblasts significantly sup- 
pressed colony formation of these cells. In contrast, transfection 
with LIMK1 antisense cDNA strongly stimulated colony 
tormation of the NIH3T3 cells• These findings suggest that 
I~IMK1 functions as a negative regulator of fibroblast cell 
~:rowth, and may play a role in tumor suppression. 
i£ey words: Growth suppression; Protein kinase; LIM motif: 
J)HR/PDZ domain; LIMK 
• Introduction 
threonine kinase activity and is mainly localized in the cyto- 
plasm [3]. The LIMK1 gene was assigned on human chromo- 
some 7q11.23 [3], and a recent report suggests that hemizy- 
gosity of the LIMK1 gene leads to impaired visuospatial 
cognition in patients of Williams' syndrome [17]. The unique 
structural features of L IMK family kinases suggest heir spe- 
cific roles in previously uncharacterized signaling pathways, 
but the cellular functions of these kinases remain to be deter- 
mined. We have now examined the effects of overexpression 
of LIMK1 on cell proliferation of NIH3T3 and Ras-trans- 
formed FYJ I0 fibroblasts. Using an induced expression sys- 
tem and colony formation assay, we found that ectopic ex- 
pression of L IMKI  significantly suppressed cell growth of 
NIH3T3 and Ras-transformed fibroblasts, Transfection of 
the antisense L IMKI  cDNA stimulated colony formation of 
NIH3T3 cells. The evidence that L IMKI  has an anti-prolif- 
erative activity on fibroblasts represents the first demonstra- 
tion of cellular functions of L IMK family kinases. 
We recently identified a novel class of closely related pro- 
~ein kinases, termed LIM-kinases (LIMKs), composed of 
~IMK1 and LIMK2 [14]. These kinases contain character- 
stic structural features of the two N-terminal LIM motifs, the 
nternal DHR (Dig homology region) (also called PDZ or 
, ]LGF)  domain, and the unusual C-terminal protein kinase 
, lomain. The LIM motif, a structural motif composed of two 
tdjacent zinc fingers separated by a 2-amino-acid linker, is 
ound in diverse proteins, including homeodomain-containing 
ranscription factors, cytoskeletal proteins and other signaling 
nolecules [5,6]. The DHR domain is a 90 100-amino-acid 
notif, previously found in various cell-junction proteins and 
~'nzymes [7,8]. Since both of these domains are thought to 
'unction as the binding surfaces of protein-protein i terac- 
ions [9 13], they are likely to be involved in the regulation 
)f kinase activity and subcellular localization of L IMK family 
~roteins. The C-terminal kinase domains of LIMKs contain a 
:onsensus equence of protein kinases, but are unique in that 
hey have an unusual sequence motif (DLNSHN) in the ki- 
lase catalytic loop in subdomain VIB and a highly basic ki- 
aase insert between subdomains VII and VIII [14]. 
LIMK1 mRNA is highly expressed in the developing nerv- 
ous system, heart and gut, and in adult brain and spinal cord 
1~,14-16], and a high level of expression in trophoblast 
giant cells has also been described [15], LIMK1 has serine/ 
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2. Materials and methods 
2.1. Cell lines and culture conditions 
NIH3T3, 208F [18] and FYJ10 (H-Ras transformed derivative of 
rat 208F fibroblast) [18] cells were maintained in Dulbecco's modified 
Eagle's medium (DMEM) supplemented with 10% fetal bovine serum 
(FBS). Rat-lA cells [19] were maintained in DMEM with 20% FBS. 
208F and FYJ10 cells were provided by Dr. R. Sch/ifer and Rat-lA 
cells by Dr. Y. Nakabeppu. 
2.2. Plasmid construction 
The 3.0-kb Apal-HindIII fragment of human LIMK1 cDNA [1] 
containing the full-size coding region was inserted into pBluescript 
SKII (Stratagene) with a NotI linker, and then subcloned into the 
NotI-digested expression vectors, pRc-RSV (Invitrogen) and pMAM- 
neo (Clontech), both of which contain the neomycin resistance gene. 
Transcription of the cDNA insert is driven by a Rous sarcoma virus 
long terminal repeat (RSV-LTR) promoter in pRc-RSV and by a 
dexamethasone (Dex)-inducible mouse mammary tumor virus 
(MMTV)-LTR promoter in the pMAMneo vector. 
2.3. Immunoprecipitation a d imrnunoblotting 
Cells were washed twice with phosphate-buffered saline, suspended 
in lysis buffer (50 mM HEPES, pH 7.4, 150 mM NaCI, 1% Nonidet 
P-40, 0.5% SDS, 10 mM NaF, 1 mM Na:~VO~, and 1 mM phenyl- 
methylsulfonyl fluoride), and incubated on ice for 30 min. Cell lysates 
from 107 cells were preadsorbed with Protein A-Sepharose (Pharma- 
cia) and the supernatants were incubated with anti-LIMKl antibodies 
and Protein A-Sepharose. Anti-LIMK1 antibodies were raised against 
the C-terminal 10 amino acids of human LIMKI and purified as 
described previously [3]. The immunoprecipitates w re washed three 
times with washing buffer (20 mM HEPES, pH 7.4, 150 mM NaCI, 
0.5% Nonidet P-40, and 1 mM dithiothreitol) and used for immuno- 
blot analysis, lmmunoblot analysis was carried out as described pre- 
viously [3]. 
2.4. Cell growth assay 
NIH3T3 cells were transfected with pMAMneo and pMAMneo- 
LIMK1 plasmids by the calcium phosphate precipitation method. 
Cells were replated at 1:20 dilution 24 h after transfection, and cul- 
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tured in DMEM in the presence of 600 gg/ml G418 (Sigma). After 2 
weeks, several independent G418-resistant clones (M5, M19 and M20 
from pMAMneo mock-transfectants and L7, L16 and LI8 from 
pMAMneo-LIMK1 transfectants) were isolated. For cell growth as- 
say, 105 cells of L7 and M19 clone were seeded in a 6-well culture 
plate and cultured in DMEM with or without 2 BM Dex. Cell num- 
bers were counted at daily intervals after plating, using a hemocyto- 
meter. 
2.5• Mieroinjection 
Microinjection assays were performed as described elsewhere [20]. 
Expression plasmids containing LIMK1, APC (adenomatous polypo- 
sis coli protein) or l~-galactosidase ([3Gal) cDNAs were injected into 
NIH3T3 cells, and 24 h later 50 l.tM bromodeoxyuridine (BrdU) was 
added. After 18 h, cells were fixed and BrdU incorporation was de- 
tected, as described [20]. 
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2.6. Colony formation assay 
NIH3T3 and FYJ10 cells were transfected by the calcium phos- 
phate method with 10 I.tg of the pRc-RSV expression plasmids con- 
taining LIMK1 cDNA in a sense (pRc-RSV-LIMKI(S)) or an anti- 
sense (pRc-RSV-LIMKI(AS)) orientation. Cells were replated at a 
1:20 dilution 24 h after transfection and cultured for 10-14 days in 
DMEM containing 10% FBS and 400-600 Bg/ml G418. Drug-resist- 
ant colonies were fixed in methanol and visualized by staining with 
0.2% crystal violet. 
3. Results 
3.1. Growth phase-dependent expression of LIMK1 protein 
Expression of LIMK1 protein during different growth 
phases in Rat - lA  fibroblasts was monitored by immunoblot 
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Fig. 1. Growth phase-dependent xpression of LIMKI protein. (A) Expression of LIMK1 protein in exponentially growing or growth-arrested 
cells. Rat-lA cells were cultured in DMEM supplemented with 20% FBS, grown to confluence, and growth-arrested by serum starvation for 
48 h. Cell densities in lanes 14 were 0.75, 2.7, 2.0, 1.9× 105 cells/cm 2, respectively. Lysates prepared from 107 cells, in exponentially growing 
(lane 1) or cultured to confluence (lane 2) and serum-starved for 24 and 48 h (lanes 3,4), were immunoprecipitated with anti-LIMK1 antibodies, 
run on SDS-PAGE, and immunoblotted with the same antibody. (B) Expression of LIMK1 protein in response to serum stimulation. Rat-lA 
cells were grown to confluence, serum-starved for 48 h and then stimulated to re-enter the cell cycle by addition of 20% FBS. Lysates from 10 7 
cells cultured for the indicated number of hours after serum stimulation were analyzed as in (A). Lower panel shows the level of DNA syn- 
thesis, as measured by incorporation of BrdU. (C) Expression of LIMKI protein in 208F (N) and H-Ras-transformed 208F (T) cell lines. Ly- 
sates from 107 cells cultured to confluency were analyzed as in (A). Arrows indicate the predicted elution positions of LIMK1 (74 kDa) and 
immunoglobulin heavy chain (IgGh) (50 kDa). 
~. Higuchi et al./FEBS Letters 396 (1996) 81~86 
A MI9  L7  






-i -i- v"x (*) /'l'~i MI9  Tlo -O- ~-) I~ lo 
S 
25 50 75 100 25 50 75 lO0 
T ime (hi T ime {hi 
~ig. 2. Induced expression of LIMKI suppresses growth of NIH3T3 
~ells. (A) Expression of LIMK1 protein in response to Dex treat- 
nent. NIH3T3 cell lines transfected with pMAMneo (M19) or 
~MAMneo-LIMK1 (L7) were cultured with or without 2 I-tM Dex 
or 48 h and the expression of LIMK1 protein was evaluated by im- 
nunoblot analysis after immunoprecipitation, using anti-LIMK1 
tntibodies. Arrows indicate the predicted elution positions of 
LIMK1 (74 kDa) and IgGh (50 kDa). (B) Growth curves of MI9 
md L7 cells. Cells were seeded on 6-well culture plates at a density 
)f 105 cells/well and cultured in DMEM containing 10% FBS with 
closed squares) or without (open squares) 2 ~tM Dex. Cell numbers 
vere counted at the indicated time. 
malysis, using anti-LIMK1 antibodies. Asynchronized, log- 
phase cultures were grown to confluence and then serum- 
~tarved and left for an additional 2 days to arrest growth 
~ompletely, and to attain a quiescent state. Expression of 
LIMK1 protein was detected in asynchronized, exponentially 
growing cells, but was barely evident in growth-arrested cells 
either cultured to confluency or serum-starved for 1-2 days 
~Fig. IA). Rat-lA cells cultured to confluency and serum- 
~tarved for 48 h were stimulated with 20% serum to re-enter 
the cell cycle, and the cell cycle-regulated expression of 
LIMK1 protein was analyzed (Fig. 1B). Immunoblot analysis 
revealed that expression of LIMK1 protein was induced at 9 h 
after serum stimulation and remained at maximal level for up 
to 24 h. BrdU incorporation analysis indicated that DNA 
synthesis began at 12 h after serum stimulation. Thus, expres- 
sion of LIMK1 protein was induced by serum stimulation 
prior to entry to DNA synthesis, and was retained during 
cell cycle progression. Expression of LIMK1 protein was 
not detectable in 208F fibroblasts cultured to confluency, 
but was detectable in H-Ras-transformed 208F cells cultured 
under similar conditions (Fig. 1C). In some experiments (Figs. 
1B and 2A), LIMK1 protein was detected as a doublet, but 
not in others (Fig. 1A,C), the reason for which has remained 
unclear. Based on the predicted molecular mass (74 kDa) of 
83 
LIMK1 protein and the elution positions of the doublet 
bands, the lower and upper band might be an intact and a 
phosphorylated form of LIMK1 protein, respectively. 
3.2. Growth suppression fNIH3T3 cells by induced expression 
of LIMK1 
The growth phase-dependent xpression of LIMK1 protein 
in Rat-lA cells suggested the possible involvement of LIMK1 
in the regulation of growth of fibroblasts. To examine the 
effect of LIMK1 expression on cell growth, we first attempted 
to generate NIH3T3 cell lines which constitutively overex- 
pressed LIMK1, using a pRc-RSV expression vector, how- 
ever, this approach was not rewarding, presumably because 
LIMK1 suppressed the growth (see below and Fig. 3). We 
therefore generated NIH3T3 cell clones that could inducibly 
overexpress LIMK1. The pMAMneo-LIMK1 expression plas- 
mid we constructed has LIMK1 cDNA under the control of a 
Dex-inducible MMTV-LTR promoter, and a neomycin resist- 
ance gene for selection of transformant cells. NIH3T3 cells 
were transfected with pMAMneo-LIMK1 or pMAMneo vec- 
tor and cultured for 2 weeks in the presence of G418. Several 
independent drug-resistant clones were picked up and ana- 
lyzed for Dex-inducible xpression of LIMKI protein. As 
shown in Fig. 2A, L7 cells, obtained by transfection with 
pMAMneo-LIMK1, inducibly expressed LIMK1 protein by 
the addition of Dex, while M19 cell lines, mock-transfected 
with pMAMneo vector, did not induce LIMK1 expression. 
The growth curves for L7 and M19 cells cultured with or 
without Dex indicate significant growth retardation of L7 cells 
due to treatment with Dex (Fig. 2B). Treatment with Dex 
reduced cell growth by approx. 40% in LIMKl-transfected 
L7 cells, but by only about 20% in mock-transfected M19 
cells. Similar results were obtained in other independent 
LIMK1- (L16 and L18) or mock-transfected (M5 and M20) 
cell lines. The doubling time of L7 cells was extended from 
26.7 to 32.5 h by culturing with Dex, while that of M19 cells 
was unchanged (22.9 to 23.1 h). No significant change was 
observed in the cell cycle profiles of L7 cells cultured for 72 h 
with or without Dex, as measured by flow cytometric analysis 
of the DNA content (data not shown). Thus, the overexpres- 
sion of LIMK1 retarded cell growth, but did not cause cell 
cycle arrest at any specific stage. In addition, exposure of L7 
cells to Dex for up to 86 h did not cause cell death, based on 
gross visual inspection. 
3.3. Inhibition of colony formation of fibroblasts by LIMK1 
To determine further the potential of LIMK1 to inhibit cell 
growth, we made use of a colony formation assay. The pRc- 
RSV expression plasmids containing LIMK1 cDNA in either 
sense or antisense orientation were constructed. These plas- 
mids are under the control of RSV LTR promoter for high- 
level and constitutive transcription and contain a neomycin 
resistance gene for selection of transformant cells. NIH3T3 
cells were transfected with the plasmids and cultured in the 
presence of G418 and drug-resistant colonies were visualized 
after 10 days of this transfection. Cells transfected with the 
LIMK1 sense cDNA expression plasmid formed fewer colo- 
nies than did those transfected with the control pRc-RSV 
vector (Fig. 3A,B). In contrast, the number of G418-resistant 
colonies recovered after transfection with antisense LIMK1 
cDNA was significantly (3-4 times) higher than seen with 
the control vector (Fig. 3C). Therefore, LIMK1 apparently 
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Fig. 3. G418-resistant colony formation assay. LIMKI cDNA was inserted into the pRc-RSV expression vector in a sense (S) or an antisense 
(AS) orientation. Left panels (A-C); NIH3T3 cells were transfected with pRc-RSV vector (A), pRc-RSV-LIMKI(S) (B), or pRc-RSV-LIM- 
KI(AS) (C), and grown in DMEM containing 10% FBS and G418 (600 gg/ml). After 10 days, drug-resistant colonies were fixed with methanol 
and stained with crystal violet. Right panels (D,E); FYJ10 cells were transfected with pRc-RSV vector (D) or pRc-RSV-LIMKI(S) (E), and 
grown in DMEM containing 10% FBS and G418 (400 ~tg/ml). After 14 days, drug-resistant colonies were fixed and stained. Results were repro- 
ducible in triplicate xperiments repeated twice. 
functions as a negative regulator of growth of NIH3T3 cells. 
Morphologic transformation (focus formation in monolayer 
cultures) was not observed in any of the transfectants. In a 
similar manner, we also examined the effect of L IMK1 on 
growth of activated Ras-transformed rat embryonic fibroblast 
FYJ10 cells. The number of colonies recovered after transfec- 
t ion with sense L IMK1 cDNA was markedly reduced, when 
compared with the case of transfection with the control vector 
( ~. Higuchi et al./FEBS Letters 396 (1996) 81~6 
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NIH3T3 cells were microinjected with the plasmids, and BrdU incorporation was detected as described in Section 2. 
g Fig. 3D,E). Thus, overexpression of LIMK1 significantly 
,-uppressed the growth of both NIH3T3 and FYJ10 fibroblast 
, ells. 
.4. Microinjection assays 
To elucidate the mechanism by which LIMK1 inhibits cell 
! rowth, microinjection experiments were carried out. Injection 
,f the plasmid containing LIMK1 cDNA into NIH3T3 cells 
l id not inhibit DNA synthesis, as determined by BrdU incor- 
,oration, whereas under similar conditions, injection of APC 
DNA significantly inhibited BrdU incorporation (Table 1). 
f'hus, growth suppression induced by LIMK1 is not due to 
he cell cycle arrest at the G1 phase. 
I. Discussion 
Using inducible expression experiments and colony forma- 
ion assays, we obtained evidence that L IMKI suppressed the 
:growth of fibroblasts. Our finding that transfection of LIMK1 
mtisense cDNA increased the number of drug-resistant colo- 
lies of NIH3T3 cells suggests that endogenously expressed 
LIMK1 normally functions as a negative regulator in cell 
;rowth. However, the mechanisms by which LIMK1 inhibits 
-ell growth seem to differ from those of other typical growth 
mppressors, uch as p53, pRB (retinoblastoma protein) and 
:yclin-dependent kinase inhibitors [21,22]. Overexpression of
LIMK1 retarded cell growth but, in contrast to the aforemen- 
tioned growth suppressors, did not arrest he cell cycle at any 
~pecific stage, as determined by flow cytometry. Microinjec- 
tion of LIMKI cDNA did not prevent cells from entering the 
S phase. Thus, LIMKI appears to have growth inhibitory 
~ffects not by directly blocking the cell cycle progression ma- 
:hinery, but rather by affecting other processes distally related 
to cell proliferation, such as the regulation of protein and 
RNA synthesis and cytoskeletal organization. The patterns 
of expression of LIMK1 protein (higher expression i  growing 
phase than in resting phase, and higher expression in Ras- 
transformed fibroblasts than in parental cells) suggest hat 
LIMK1 functions in the growing stage and may play a role 
of slowing the pace of the cell cycle by regulating certain 
events in this phase. Further studies are required to resolve 
the question of how LIMK1 retards cell growth. In particular, 
identification of the upstream regulators and downstream tar- 
gets of LIMK1 will be important. 
LIMK1 contains a unique extracatalytic domain composed 
of two LIM motifs at the N-terminus and a DHR domain at 
the internal region. These structural motifs likely have roles in 
the cellular functions of LIMK1. The LIM motif was identi- 
fied in diverse proteins, some of which were found to be in- 
volved in growth regulation and oncogenesis [5,6]. As the 
LIM motifs are thought to be involved in protein-protein 
interactions, the LIM motifs in L IMKI probably function 
as binding modules to interact with other signaling proteins. 
LIMKl-associated proteins were detected by co-immunopre- 
cipitation analysis, but the molecular properties of these pro- 
teins have remained to be identified [3,14]. Further identifica- 
tion and characterization f LIMKl-associated proteins will 
serve to elucidate the mechanisms of anti-proliferative activity 
of LIMK1. Additionally, LIMK1 contains a DHR domain in 
the internal region of the molecule. Drosophila Dlg (Disc 
large) protein, after which the DHR domain was named, is 
localized to septate junctions in imaginal disc epithelia nd is 
known as a tumor suppressor protein, since its mutation 
causes neoplastic proliferation of epithelial cells [23]. Recently, 
a human homolog of Dlg was found to bind through its DHR 
domain to APC protein, a product of the tumor suppressor 
gene mutated in familial adenomatous polyposis and sporadic 
colorectal tumors [13]. Thus, it is likely that in both verte- 
brates and invertebrates Dig protein functions as a tumor 
suppressor by the DHR-mediated association with APC. 
While the mechanism by which LIMKI suppresses cell growth 
is unclear, the DHR domain of LIMKI may be involved in 
growth suppressing activity by forming a complex with APC 
or related proteins. 
The growth inhibitory activity of LIMKI raises the possi- 
bility that genes of LIMK1 and its relative LIMK2 may func- 
tion as novel tumor suppressors. The chromosomal localiza- 
tion of human LIMK1 and LIMK2 genes was assigned to 
7q11.23 and 22q12, respectively [3]. The LIMK1 gene was 
recently suggested to be one of the causal genes of Williams' 
syndrome [17]. The locus of the LIMK2 gene is close to that 
of the tumor suppressor gene NF2 (neurofibromatosis 2) [24], 
Since loss on 22q near to but outside the NF2 locus was 
detected in some cases of menigiomas, gliomas, ovarian car- 
cinoma and colorectal cancers [25-27], inactivation of the 
LIMK2 gene may be linked to the tumorigenesis of these 
cancers. 
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